FANTOM

FANTOM
Name	FANTOM
Formation	2000s
Type	International research consortium
Headquarters	RIKEN
Location	Japan
Field	Genomics, Transcriptomics, Epigenomics
Leader	Yoshihide Hayashizaki

FANTOM FANTOM is a large-scale international consortium focused on mapping and characterizing functional elements of mammalian transcriptomes and regulatory landscapes. The initiative has produced comprehensive atlases of promoters, enhancers, and noncoding RNAs across cell types and developmental stages, influencing projects in genomics, transcriptomics, and epigenomics. Its outputs are widely used alongside resources from ENCODE Project and GTEx Consortium to annotate regulatory networks in human and mouse biology.

Overview

FANTOM operates as a collaboration among institutions such as RIKEN, Wellcome Trust Sanger Institute, European Bioinformatics Institute, University of Tokyo, and National Institutes of Health. The consortium integrates technologies developed at places like RIKEN Omics Science Center and in partnerships with companies including Illumina and Pacific Biosciences. Its work interfaces with initiatives like Roadmap Epigenomics Project, Human Cell Atlas, ENCODE Project, GTEx Consortium, and datasets produced by 1000 Genomes Project. Leadership and key contributors have included researchers associated with Yoshihide Hayashizaki, Piero Carninci, Charles Auffray, and collaborators from Cold Spring Harbor Laboratory.

History and Development

FANTOM began in the early 2000s following advances at RIKEN and grew through successive phases—FANTOM1, FANTOM2, FANTOM3, FANTOM4, FANTOM5—each expanding scope and technology. Early stages emphasized full-length cDNA cloning influenced by work at MRC Laboratory of Molecular Biology and techniques derived from studies at Pasteur Institute. Later phases adopted Cap Analysis of Gene Expression (CAGE) protocols optimized in coordination with platforms at Illumina and analytic frameworks similar to those used by Broad Institute teams. Milestones include comprehensive promoter atlases and enhancer catalogs that paralleled releases from ENCODE Project and complements provided by Roadmap Epigenomics Project.

Composition and Key Components

The consortium comprises research groups from institutions including RIKEN, Sanger Institute, EMBL-EBI, University of California, San Diego, Keio University, and Osaka University. Core components are technology platforms such as CAGE, single-molecule sequencing implemented by Pacific Biosciences and long-read methods developed at Oxford Nanopore Technologies, and computational pipelines interoperable with resources at GitHub-hosted projects and analysis tools influenced by work at Wellcome Trust Sanger Institute and Broad Institute. Data coordination leverages standards practiced at International Nucleotide Sequence Database Collaboration and sample metadata conventions akin to those of the Sequence Read Archive.

Biological Functions and Mechanisms

FANTOM atlases illuminate transcription initiation landscapes, enhancer–promoter interactions, and long noncoding RNA (lncRNA) activities across cell types such as those studied at Harvard Medical School, Stanford University School of Medicine, and University of Cambridge. Analyses reveal tissue-specific promoter usage comparable to observations in datasets from GTEx Consortium and enhancer dynamics similar to patterns reported by Roadmap Epigenomics Project. Mechanistic insights relate to transcription factor binding events characterized in studies at EMBL-EBI and regulatory networks intersecting with pathways researched at National Cancer Institute and Max Planck Institute laboratories.

Major Projects and Datasets

FANTOM5 represents a landmark project producing promoter and enhancer atlases for human and mouse cell types, akin to landmark releases by ENCODE Project and GTEx Consortium. Other products include comprehensive CAGE libraries, full-length cDNA collections comparable to resources at GenBank and RefSeq, and enhancer catalogs used by groups at Wellcome Trust Sanger Institute and European Molecular Biology Laboratory. The datasets have been integrated into browsers and portals used by UCSC Genome Browser, Ensembl, and analytic platforms at EBI Europe.

Applications and Impact

FANTOM resources underpin research in developmental biology at institutions like Max Planck Institute for Molecular Cell Biology and Genetics, disease studies at Dana-Farber Cancer Institute and Johns Hopkins University, and translational efforts in pharmaceutical research at Novartis and Pfizer. The atlases inform variant interpretation performed in clinical pipelines at Mayo Clinic and population genetics analyses related to 1000 Genomes Project and UK Biobank workflows. FANTOM outputs also support single-cell initiatives pursued by Broad Institute and Wellcome Sanger Institute.

Criticisms and Limitations

Critiques of FANTOM include comparisons with projects such as ENCODE Project over definitions of functionality, reproducibility concerns raised in discussions involving groups from Harvard University and MIT, and debates on cell-type sampling completeness highlighted by teams at Human Cell Atlas. Limitations encompass technology biases inherent to CAGE and sequencing platforms like Illumina and Oxford Nanopore Technologies, sample representation issues noted by researchers at GTEx Consortium, and integration challenges with epigenomic maps generated by Roadmap Epigenomics Project.

Category:Genomics projects